Biogen Inc (BIIB)

TradeGate
Currency in EUR
Disclaimer
281.40
+0.60
(+0.21%)
Closed
Day's Range
279.20
282.40
52 wk Range
178.86
321.50
Volume
106
Bid/Ask
281.40 / 282.00
Prev. Close
280.8
Open
279.2
Day's Range
279.2-282.4
52 wk Range
178.86-321.5
Volume
106
Average Volume (3m)
303
1-Year Change
48.62%
Shares Outstanding
144,742,368
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
332.38
Upside +10.01%

People Also Watch

444.26
LLY
+0.44%
442.84
INTU
+2.87%
802.30
AVGO
-1.19%

Biogen Inc News

Biogen Inc Analysis

Biogen Inc Company Profile

Biogen Inc. is a global biotechnology company. The Company is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. It is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD), BIIB080 for Alzheimer's disease, tofersen for amyotrophic lateral sclerosis (ALS) and both litifilimab and dapirolizumab pegol for certain forms of lupus.

Employees
9610